Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
In a further bid to expand its already lucrative portfolio of metabolic and obesity medicines, Denmark’s Novo Nordisk has entered into an exclusive global collaboration and license agreement with USA-based Septerna to discover, develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. 14 May 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Biotechnology
Chicago-based pharma major AbbVie and privately-held San Diego biotech ADARx Pharmaceuticals have announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. 14 May 2025
Pharmaceutical
In a further bid to expand its already lucrative portfolio of metabolic and obesity medicines, Denmark’s Novo Nordisk has entered into an exclusive global collaboration and license agreement with USA-based Septerna to discover, develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. 14 May 2025
Pharmaceutical
US biotech Cytokinetics has unveiled fresh Phase III data backing its heart drug aficamten, showing the treatment was more effective than the standard beta blocker metoprolol in patients with obstructive hypertrophic cardiomyopathy. 14 May 2025
Biotechnology
UK-based Kaerus Bioscience, a biopharma created by European investment firm Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, has announced that its lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). 14 May 2025
Pharmaceutical
New York-based Axsome Therapeutics, a biopharma focused on central nervous system (CNS) disorders, has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit and Insurance. 14 May 2025
Pharmaceutical
Danish CNS specialist Lundbeck today released first-quarter 2025 financials, along with a raised guidance for the full year, sending its shares up more than 9% to 28.80 kroner. 14 May 2025
Biotechnology
Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round. 13 May 2025
Pharmaceutical
They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data presented by Eli Lilly—they have gone up against one another. 13 May 2025
Pharmaceutical
Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide injection) 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 37% in adults with overweight and obesity and cardiovascular (CV) disease, compared to placebo, on top of standard of care, within the first three months of treatment. 13 May 2025
Latest In Brief for Novo Nordisk
Latest Related Ones To Watch News
USA-based Medicus Pharma has agreed to acquire UK firm Antev for around $75 milln in a share exchange deal. 28 April 2025
17 April 2025
17 March 2025
11 March 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze